RecruitingPhase 2NCT06261060
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Studying Familial platelet disorder with associated myeloid malignancy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Courtney DiNardo, MDM.D. Anderson Cancer Center
- Intervention
- Sirolimus(drug)
- Enrollment
- 6 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06261060 on ClinicalTrials.govOther trials for Familial platelet disorder with associated myeloid malignancy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06414889Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet DisorderM.D. Anderson Cancer Center
- RECRUITINGNCT03854318Longitudinal Studies of Patient With FPDMMNational Human Genome Research Institute (NHGRI)
See all trials for Familial platelet disorder with associated myeloid malignancy →